Document Detail

Cisplatin-associated anaemia in patients with solid tumours. A retrospective evaluation and considerations relative to erythropoietin administration.
MedLine Citation:
PMID:  8739656     Owner:  NLM     Status:  MEDLINE    
We have reviewed the incidence of cisplatin-induced anaemia in patients affected with solid tumours treated with at least three courses of first-line cisplatin-containing regimens. In our experience, a low percentage (5%) of patients required transfusions of red blood cells. We think it is of the utmost importance to adopt uniform criteria in monitoring and treatment of patients at risk of developing cisplatin anaemia and to identify subsets of patients to eventually treat with erythropoietin.
M C Locatelli; L Tedeschi; M Clerici; A Romanelli; A D'Antona; R Labianca; G Luporini
Related Documents :
8218536 - Factors associated with transfusion requirements during treatment for acute myelogenous...
1130436 - Sickle cell anemia- clinical manifestations in 100 patients and review of the literature.
16424656 - Diastolic dysfunction and pulmonary hypertension in sickle cell anemia: is there a role...
8154276 - Autologous blood transfusion with recombinant erythropoietin treatment. 22 arthroplasti...
22294096 - Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous...
25424576 - Olfactory impairment in patients with the fibromyalgia syndrome and systemic sclerosis.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer     Volume:  4     ISSN:  0941-4355     ISO Abbreviation:  Support Care Cancer     Publication Date:  1996 May 
Date Detail:
Created Date:  1996-10-10     Completed Date:  1996-10-10     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9302957     Medline TA:  Support Care Cancer     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  218-9     Citation Subset:  IM    
Medical Oncology Department, S. Carlo Borromeo Hospital, Milan, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia / chemically induced*,  drug therapy,  therapy
Antineoplastic Agents / administration & dosage,  adverse effects*
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use
Cisplatin / administration & dosage,  adverse effects*
Erythrocyte Transfusion
Erythropoietin / administration & dosage,  therapeutic use*
Evaluation Studies as Topic
Lung Neoplasms / drug therapy*
Ovarian Neoplasms / drug therapy*
Prostatic Neoplasms / drug therapy*
Retrospective Studies
Risk Factors
Reg. No./Substance:
0/Antineoplastic Agents; 11096-26-7/Erythropoietin; 15663-27-1/Cisplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The role of bisphosphonates in the treatment of bone metastases--the U.S. experience.
Next Document:  A 5-year follow-up study of suicide attempts.